Prime Medicine to Present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025.

Chardan's 9th Annual Genetic Medicines Conference is scheduled for October 21, 2025, at 8:45 AM EDT. The conference will feature Prime Medicine, Inc. as a presenter. The webcast link is available on the conference webpage.

Chardan's 9th Annual Genetic Medicines Conference, scheduled for October 21, 2025, at 8:45 AM EDT, will feature two notable presenters: Senti Biosciences and Prime Medicine Inc. The webcast link for the conference is available on the event webpage Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference^[1].

Senti Biosciences, a clinical-stage biotechnology company specializing in next-generation cell and gene therapies, will be represented by its CEO, Timothy Lu. Lu will discuss the company's advancements in cell and gene therapies using the Gene Circuit platform. Senti Bio's focus is on developing enhanced therapies targeting cancer and other diseases, with promising preclinical results in manipulating T and NK cells. The presentation will be available via live webcast on the company's website Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference^[1].

Prime Medicine Inc., a biopharmaceutical company, will also be presenting at the conference. The company's focus is on developing next-generation medicines for various diseases. The specific details of Prime Medicine's presentation are not yet available, but their inclusion at a prominent industry conference highlights their growing recognition in the biotechnology sector Prime Medicine, Inc.'s (NASDAQ:PRME) 6.6% loss last week hit both individual investors who own 30% as well as institutions^[2].

The conference provides an excellent opportunity for investors to engage with both companies directly. Senti Bio will participate in one-on-one meetings with qualified investors, while Prime Medicine Inc. will be available for discussions as well. The event underscores the importance of transparency and investor engagement in the biotechnology industry.

This conference comes at a crucial time for both companies, as they continue to advance their innovative therapies. For Senti Bio, the presentation and investor meetings offer a platform to showcase their cutting-edge Gene Circuit technology and attract potential investment. For Prime Medicine Inc., the conference provides an opportunity to highlight their advancements and engage with the investment community.

Investors and financial professionals are encouraged to tune in to the webcast and participate in the conference to gain insights into the latest developments in genetic medicines and biotechnology.